Candel Therapeutics (CADL) Competitors

$7.66 -0.24 (-3.04%)

Closing price 04:00 PM Eastern

Extended Trading

$7.68 +0.01 (+0.20%)

As of 06:07 PM Eastern

CADL vs. RLAY, MLYS, HCM, ADPT, and NBTX

Should you buy Candel Therapeutics stock or one of its competitors? MarketBeat compares Candel Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Candel Therapeutics include Relay Therapeutics (RLAY), Mineralys Therapeutics (MLYS), HUTCHMED (HCM), Adaptive Biotechnologies (ADPT), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry.

How does Candel Therapeutics compare to Relay Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Candel Therapeutics had 6 more articles in the media than Relay Therapeutics. MarketBeat recorded 19 mentions for Candel Therapeutics and 13 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.56 beat Candel Therapeutics' score of 0.09 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Relay Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics has a beta of -0.59, suggesting that its share price is 159% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market.

Candel Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Relay Therapeutics	$15.35M	150.65	-$276.48M	-$1.57	N/A

Relay Therapeutics' return on equity of -43.94% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Relay Therapeutics	N/A	-43.94%	-40.11%

Candel Therapeutics currently has a consensus price target of $18.00, indicating a potential upside of 134.99%. Relay Therapeutics has a consensus price target of $21.80, indicating a potential upside of 80.61%. Given Candel Therapeutics' higher probable upside, equities analysts plainly believe Candel Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Relay Therapeutics beats Candel Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Candel Therapeutics compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Candel Therapeutics (NASDAQ:CADL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Mineralys Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.59, suggesting that its stock price is 159% less volatile than the broader market.

Mineralys Therapeutics presently has a consensus target price of $49.33, suggesting a potential upside of 89.52%. Candel Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 134.99%. Given Candel Therapeutics' higher possible upside, analysts clearly believe Candel Therapeutics is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Mineralys Therapeutics' return on equity of -27.92% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Candel Therapeutics	N/A	-60.42%	-41.33%

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Candel Therapeutics had 8 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 19 mentions for Candel Therapeutics and 11 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.44 beat Candel Therapeutics' score of 0.09 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Mineralys Therapeutics beats Candel Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Candel Therapeutics compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Candel Therapeutics (NASDAQ:CADL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

HUTCHMED has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.59, indicating that its stock price is 159% less volatile than the broader market.

In the previous week, Candel Therapeutics had 16 more articles in the media than HUTCHMED. MarketBeat recorded 19 mentions for Candel Therapeutics and 3 mentions for HUTCHMED. Candel Therapeutics' average media sentiment score of 0.09 beat HUTCHMED's score of -0.18 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

HUTCHMED currently has a consensus price target of $16.88, indicating a potential upside of 39.93%. Candel Therapeutics has a consensus price target of $18.00, indicating a potential upside of 134.99%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

HUTCHMED has higher revenue and earnings than Candel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.84	$456.91M	N/A	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

HUTCHMED's return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Candel Therapeutics	N/A	-60.42%	-41.33%

Summary

Candel Therapeutics beats HUTCHMED on 7 of the 13 factors compared between the two stocks.

How does Candel Therapeutics compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Candel Therapeutics (NASDAQ:CADL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Adaptive Biotechnologies has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.59, suggesting that its share price is 159% less volatile than the broader market.

Candel Therapeutics has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	7.49	-$59.50M	-$0.33	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Candel Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Candel Therapeutics	N/A	-60.42%	-41.33%

Adaptive Biotechnologies presently has a consensus target price of $19.57, indicating a potential upside of 51.01%. Candel Therapeutics has a consensus target price of $18.00, indicating a potential upside of 134.99%. Given Candel Therapeutics' higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Candel Therapeutics had 15 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 19 mentions for Candel Therapeutics and 4 mentions for Adaptive Biotechnologies. Candel Therapeutics' average media sentiment score of 0.09 beat Adaptive Biotechnologies' score of -0.01 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Adaptive Biotechnologies and Candel Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Candel Therapeutics compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Candel Therapeutics (NASDAQ:CADL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Nanobiotix has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.59, meaning that its stock price is 159% less volatile than the broader market.

Nanobiotix's return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Candel Therapeutics	N/A	-60.42%	-41.33%

Nanobiotix has higher revenue and earnings than Candel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	60.80	-$27.11M	N/A	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Nanobiotix currently has a consensus price target of $26.67, indicating a potential downside of 42.28%. Candel Therapeutics has a consensus price target of $18.00, indicating a potential upside of 134.99%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Candel Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Candel Therapeutics had 17 more articles in the media than Nanobiotix. MarketBeat recorded 19 mentions for Candel Therapeutics and 2 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.60 beat Candel Therapeutics' score of 0.09 indicating that Nanobiotix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Nanobiotix beats Candel Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Candel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CADL vs. The Competition

Export

Metric	Candel Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$561.25M	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-7.82	18.70	20.58	25.11
Price / Sales	N/A	278.20	577.42	91.32
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	8.06	6.57	9.68	6.60
Net Income	-$38.18M	$24.30M	$3.55B	$335.71M
7 Day Performance	-12.16%	-3.56%	-2.07%	-2.03%
1 Month Performance	20.25%	-7.86%	-3.90%	-1.90%
1 Year Performance	34.39%	51.80%	29.39%	27.36%

Candel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CADL Candel Therapeutics	3.9273 of 5 stars	$7.66 -3.0%	$18.00 +135.0%	+47.7%	$561.25M	N/A	N/A	60	Earnings Report Analyst Upgrade Analyst Revision Gap Down
RLAY Relay Therapeutics	2.987 of 5 stars	$12.85 +0.7%	$20.56 +60.0%	+330.6%	$2.44B	$15.35M	N/A	330	Trending News Analyst Forecast Gap Up
MLYS Mineralys Therapeutics	3.8687 of 5 stars	$29.73 +0.6%	$49.14 +65.3%	+71.9%	$2.44B	N/A	N/A	28
HCM HUTCHMED	3.5191 of 5 stars	$12.87 -2.0%	$16.88 +31.1%	-10.8%	$2.29B	$548.51M	N/A	1,796	News Coverage
ADPT Adaptive Biotechnologies	3.2789 of 5 stars	$13.54 -2.0%	$20.00 +47.7%	+40.4%	$2.21B	$276.98M	N/A	790

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CADL) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Candel Therapeutics (CADL) Competitors

CADL vs. RLAY, MLYS, HCM, ADPT, and NBTX

How does Candel Therapeutics compare to Relay Therapeutics?

Summary

How does Candel Therapeutics compare to Mineralys Therapeutics?

Summary

How does Candel Therapeutics compare to HUTCHMED?

Summary

How does Candel Therapeutics compare to Adaptive Biotechnologies?

Summary

How does Candel Therapeutics compare to Nanobiotix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Candel Therapeutics (CADL) Competitors

CADL vs. RLAY, MLYS, HCM, ADPT, and NBTX

How does Candel Therapeutics compare to Relay Therapeutics?

Does the media prefer CADL or RLAY?

Which has more volatility & risk, CADL or RLAY?

Which has better earnings & valuation, CADL or RLAY?

Is CADL or RLAY more profitable?

Do analysts recommend CADL or RLAY?

Do institutionals and insiders hold more shares of CADL or RLAY?

Summary

How does Candel Therapeutics compare to Mineralys Therapeutics?

Which has better valuation and earnings, MLYS or CADL?

Which has more risk and volatility, MLYS or CADL?

Do analysts rate MLYS or CADL?

Is MLYS or CADL more profitable?

Do institutionals and insiders have more ownership in MLYS or CADL?

Does the media refer more to MLYS or CADL?

Summary

How does Candel Therapeutics compare to HUTCHMED?

Which has more risk and volatility, HCM or CADL?

Does the media prefer HCM or CADL?

Do institutionals & insiders believe in HCM or CADL?

Do analysts prefer HCM or CADL?

Which has stronger valuation & earnings, HCM or CADL?

Is HCM or CADL more profitable?

Summary

How does Candel Therapeutics compare to Adaptive Biotechnologies?

Which has more risk & volatility, ADPT or CADL?

Which has better earnings and valuation, ADPT or CADL?

Is ADPT or CADL more profitable?

Do analysts prefer ADPT or CADL?

Does the media prefer ADPT or CADL?

Do institutionals and insiders believe in ADPT or CADL?

Summary

How does Candel Therapeutics compare to Nanobiotix?

Which has more volatility & risk, NBTX or CADL?

Is NBTX or CADL more profitable?

Which has better earnings & valuation, NBTX or CADL?

Do analysts prefer NBTX or CADL?

Does the media refer more to NBTX or CADL?

Do insiders & institutionals have more ownership in NBTX or CADL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools